pepdex
← Back to index
№ 064

Pemvidutide

Altimmune's GLP-1 + glucagon dual agonist. Phase 2 data shows weight loss alongside meaningful liver-fat reduction (NASH/MASH applications). Direct competitor to Retatrutide and Survodutide.

Fat Loss
Evidence: Moderate
Half-life
~5 days
Route
Subcutaneous
Cycle
Trial protocols
Schedule
Once weekly
In plain English

Pemvidutide is Altimmune's competitor to Retatrutide and Survodutide — a GLP-1 + glucagon dual agonist. The interesting thing about Pemvidutide is it shows real liver-fat reduction in addition to weight loss, making it a NASH/MASH drug candidate too. Phase 2 in development.

Status & legality
Natty?
Not natty
FDA
Not approved

Investigational. Phase 2 trials by Altimmune for obesity and NASH/MASH.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Trial access only.

Who it's for

  • →Trial participants in NASH/MASH or obesity studies
  • →Patients with metabolic-syndrome plus liver involvement
  • →Followers of Altimmune's pipeline

What to expect

  1. Week 1

    Appetite drops. Mild nausea. Slight body-temp uptick from glucagon arm.

  2. Week 4

    First titration step. Weight loss tracking.

  3. Week 8

    Phase 2 showed liver-fat reduction beginning to compound.

How it works (mechanism)

GLP-1 + glucagon dual agonist with structural design favoring liver-fat reduction alongside weight loss, making it a NASH/MASH candidate as well as obesity.

Dosing protocol

Trial doses 1.2-2.4 mg weekly. Titrate over 4-week steps.

Stacks well with

Standalone in current trials

Side effects

01Nausea (titration steps)
02Diarrhea
03Mild HR increase (glucagon effect)
04Fatigue

When NOT to use

  • ⚠MTC / MEN-2 history
  • ⚠Pancreatitis history
  • ⚠Severe cardiovascular disease
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Lipid panel
  • • ALT/AST
  • • Liver imaging if NASH context
  • • A1C

Common mistakes

  • • Treating elevated HR as caffeine sensitivity
  • • Titrating too fast
  • • Not getting baseline liver imaging if NASH-related

Drug & supplement interactions

  • ⚠Same GLP/glucagon class warnings
  • ⚠Trial-only — full interaction profile not yet published

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Pemvidutide?+
Pemvidutide is Altimmune's competitor to Retatrutide and Survodutide — a GLP-1 + glucagon dual agonist. The interesting thing about Pemvidutide is it shows real liver-fat reduction in addition to weight loss, making it a NASH/MASH drug candidate too. Phase 2 in development.
Is Pemvidutide FDA approved?+
Investigational. Phase 2 trials by Altimmune for obesity and NASH/MASH.
Is Pemvidutide banned by WADA?+
Pemvidutide is not currently on the WADA prohibited list.
Are you still natty after taking Pemvidutide?+
No. Pemvidutide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Pemvidutide?+
Trial access only.
What's the typical dose of Pemvidutide?+
Trial doses 1.2-2.4 mg weekly. Titrate over 4-week steps.
What are the side effects of Pemvidutide?+
Common side effects include: Nausea (titration steps); Diarrhea; Mild HR increase (glucagon effect); Fatigue. Less common effects and full safety details are on the entry page.
How long until Pemvidutide starts working?+
Appetite drops. Mild nausea. Slight body-temp uptick from glucagon arm.

More in Fat Loss

№ 008
Tirzepatide

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

№ 009
Semaglutide

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 058
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.